Orgenesis CEO Vered Caplan to Present at T1D Exchange Annual Meeting

Orgenesis CEO Vered Caplan to Present at T1D Exchange Annual Meeting

ID: 501848

(firmenpresse) - GERMANTOWN, MD -- (Marketwired) -- 10/20/16 -- (OTCQB: ORGS), a fully integrated cell therapy and contract development and manufacturing company, announced that Orgenesis CEO, Vered Caplan, will present at the T1D Exchange 4th Annual Meeting, which is being held at the Royal Sonesta Hotel in Boston, Massachusetts on October 21, 2016. Ms. Caplan will speak on the panel "Cellular and Biopharmaceutical Innovations."

The T1D Exchange Annual Meeting is designed to bring together the members -- global diabetes stakeholders from industry, foundation, investment and research -- to foster collaborations and generate new ideas that can improve outcomes in Type 1 Diabetes. The T1D Exchange Annual Meeting convenes more than 175 key industry participants to exchange unique perspectives and robust ideas around innovations in care. Together, these stakeholders will explore important topics including innovations in understanding the origin of T1D, cellular and biopharmaceutical innovations, device, digital health solutions and decision-making support and translating innovations.



Orgenesis is a fully integrated cell therapy and regenerative medicine company. The Company is providing manufacturing services for other cell therapy markets in such areas as cell-based cancer immunotherapies and autoimmune diseases. In addition, through its subsidiary, Orgenesis Ltd, the Company is developing a cure for diabetes using a novel "cellular trans-differentiation" technology that transforms an insulin-dependent patient's own adult cells into functional insulin producing cells. The Company has demonstrated that, when exposed ex-vivo to certain pancreatic transcription factors and in specific sequence, human adult cells can be transformed into fully functional, beta cell-like insulin producing cells. Orgenesis Ltd has an exclusive license from Tel Hashomer Hospital for intellectual property directed to the cellular trans-differentiating technology.





David Waldman
Crescendo Communications, LLC
(212) 671-1020 x301

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Vitality Biopharma Reports on Initial Cannabinoid Drug Formulation Studies Luvu Brands Expands Jaxx Production Line
Bereitgestellt von Benutzer: Marketwired
Datum: 20.10.2016 - 14:19 Uhr
Sprache: Deutsch
News-ID 501848
Anzahl Zeichen: 0

contact information:
Town:

GERMANTOWN, MD



Kategorie:

Personal Care & Fitness



Diese Pressemitteilung wurde bisher 354 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Orgenesis CEO Vered Caplan to Present at T1D Exchange Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von

Orgenesis Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Orgenesis to Present at BIO Investor Forum ...

GERMANTOWN, MD -- (Marketwired) -- 10/18/17 -- Orgenesis Inc., (OTCQB: ORGS) ("Orgenesis " or "the Company"), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and ...

Orgenesis to Present at the 2017 Marcum MicroCap Conference ...

GERMANTOWN, MD -- (Marketwired) -- 06/12/17 -- (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing, today announced that it will be presenting at the on ...

Alle Meldungen von Orgenesis Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z